Federal Register / Vol. 72, No. 11 / Thursday, January 18, 2007 / Notices 2287 

For Further Information Contact: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Charles Land, 

Project Officer, National Cancer 

Institute, EPS , 6120 Executive 

Boulevard MSC 7238, Bethesda, 

Maryland 20852, or call non-toll free 

number 301–594–7165 or FAX your 

request, including your address to 301–

402–0207. 

Comments Due Date 

Comments regarding this information 

collection are best assured of having 

their full effect if received within 60 

days of this publication. 

Dated: January 8, 2007. 

Rachelle Ragland-Greene, 

NCI Project Clearance Liaison, National 

Institutes of Health. 

[FR Doc. E7–625 Filed 1–17–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Novel Benztropine Analogs for 

Treatment of Cocaine Abuse and Other 

Mental Disorders 

Description of Technology: Dopamine 

is a neurotransmitter that exerts 

important effects on locomotor activity, 

motivation and reward, and cognition. 

The dopamine transporter (DAT) is 

expressed on the plasma membrane of 

dopamine synthesizing neurons, and is 

responsible for clearing dopamine 

released into the extra-cellular space, 

thereby regulating neurotransmission. 

The dopamine transporter plays a 

significant role in neurotoxicity and 

human diseases, such as Parkinson’s 

disease, drug abuse (especially cocaine 

addiction), Attention Deficit Disorder/ 

Attention Deficit Hyperactivity Disorder 

(ADD/ADHD), and a number of other 

CNS disorders. Therefore, the dopamine 

transporter is a strong target for research 

and the discovery of potential 

therapeutics for the treatment of these 

indications. 

This invention discloses novel 

benztropine analogs and methods of 

using these analogs for treatment of 

mental and conduct disorders such as 

cocaine abuse, narcolepsy, ADHD, 

obesity and nicotine abuse. The 

disclosed analogs are highly selective 

and potent inhibitors of DAT, but 

without an apparent cocaine-like 

behavioral profile. In addition to their 

use as a treatment for cocaine abuse, 

these compounds have also shown 

efficacy in animal models of ADHD and 

nicotine abuse, and have also been 

shown to reduce food intake in animals. 

They may also be useful medications for 

other indications where dopaminerelated behavior is compromised, such 

as alcohol addiction, tobacco addiction, 

and Parkinson’s disease. 

Applications: Drug leads for treatment 

of cocaine abuse, ADHD, nicotine abuse, 

obesity, and other dopamine-related 

disorders; Imaging probes for dopamine 

transporter binding sites. 

Development Status: Pre-clinical data 

are available. 

Inventors: Amy H. Newman, Mu-fa 

Zou, and Jonathan L. Katz (NIDA). 

Patent Status: U.S. Provisional 

Application No. 60/710,956 filed 24 

Aug 2005 (HHS Reference No. E–234–

2005/0–US–01); PCT Application No. 

PCT/US2006/33103 filed 24 Aug 2006 

(HHS Reference No. E–234–2005/1–

PCT–01 and HHS Reference No. E–129–

2006/0). 

Licensing Status: Available for 

exclusive or nonexclusive licensing. 

Licensing Contact: Tara Kirby, Ph.D.; 

301/435–4426; tarak@mail.nih.gov. 

Collaborative Research Opportunity: 

The Medicinal Chemistry and 

Psychobiology Sections, National 

Institute on Drug Abuse-Intramural 

Research Program, National Institutes of 

Health, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize medications to treat 

cocaine abuse and addiction. Please 

contact John D. Hewes, Ph.D. at 301/ 

435–3121 or hewesj@mail.nih.gov for 

more information. 

Protein Arginine N-methyltransferase 2 

(PRMT–2), a Modulator of NFKB, E2F1, 

and STAT3 Activity 

Description of Technology: Proteinarginine methyltransferases (PRMTs) 

contain methyltransferase domains that 

modify chromatin and regulate cellular 

transcription through the posttranslational methylation of arginine 

residues on the guanidine group of 

target proteins. Members of this family 

have roles in RNA processing, 

transcriptional regulation, signal 

transduction, and DNA repair. Until 

recently, the functional significance of 

one member of this family, PRMT–2, 

was unknown. 

Researchers at NHLBI, led by Dr. 

Elizabeth Nabel, have elucidated the 

role of PRMT–2. They have found that 

PRMT–2 modulates the activity of 

NFKB, E2F1, and STAT3. PRMT–2 

inhibits NFKB dependent transcription, 

and therefore PRMT–2 has a role in 

modulating inflammation and the 

immune response. Also, PRMT–2 

proteins can repress E2F1 

transcriptional activity and cause cell 

cycle arrest, and thus may be used to 

treat or prevent cancer. PRMT–2 also 

methylates STAT3, and inhibition or 

loss of PRMT–2 function causes 

mammals to lose weight, eat less and 

become more sensitive to insulin. 

The invention describes methods of 

modulating PRMT–2 activity or 

expression in cells. These methods can 

be used to inhibit the function of NF?B, 

E2F1 and STAT3 for treatment of a 

number of disorders, including 

inflammation, cancer, and diabetes. 

Applications: Target for treatment and 

study of a number of disorders, 

including: 

Diabetes, obesity and metabolic 

syndrome diseases; Inflammation and 

immune response-related disorders; 

Cancer. 

Inventors: Elizabeth Nabel (NHLBI), 

Hiroaki Iwasaki (NHLBI), Takanobu 

Yoshimoto (NHLBI), and Gary Nabel 

(NIAID). 

Patent Status: U.S. Provisional 

Application No. 60/466,751 filed 30 

April 2003 (HHS Reference No. E–190–

2003/0–US–01); PCT Application No. 

PCT2004/013375 filed 30 April 2004, 

which published as WO 2004/098634 

on 18 Nov 2004 (HHS Reference No. E–

190–2003/0–PCT–02); U.S. Application 

No. 11/263,657 filed 31 Oct 2005, which 

published as WO 2006/0239990 on 26 


pwalker on PROD1PC71 with NOTICES
2288 Federal Register / Vol. 72, No. 11 / Thursday, January 18, 2007 / Notices 

Oct 2006 (HHS Reference No. E–190–

2003/0–US–04). 

Licensing Status: Available for 

exclusive or nonexclusive licensing. 

Licensing Contact: Tara Kirby, Ph.D.; 

301/435–4426; tarak@mail.nih.gov. 

Methods for Assaying Hair Follicle 

Growth and Development 

Description of Technology: Methods 

of culturing functionally-intact hair 

follicles in a collagen matrix are useful 

for screening baldness treatments and 

the quantification and study of the 

effects of agents on hair follicle growth. 

This technology describes techniques 

for measuring cell proliferation or for 

measuring secretion of collagenolytic 

factors, incorporating a threedimensional hair follicle culture system. 

Collagenolytic activity is essential for 

downgrowth of hair follicles during 

anagen. One described method 

measures the effects of a growth factor 

or pharmaceutical compound on cell 

proliferation, utilizing the incorporation 

of tritiated thymidine into DNA of 

cultured hair follicles. Also described is 

a method to measure the effect of 

growth factors on the release of 

collagenolytic factors, utilizing tritiated 

collagen or a fluorescent marker. 

Applications: Assays for screening 

drugs or growth factors that may 

stimulate hair growth; Assays measuring 

the DNA synthesis and collagenasesecreting activity of hair follicles. 

Market: An estimated 40 million men 

and 20 million women suffer from hair 

loss; The market size for hair restoration 

procedures in the United States is 

approximately $800 million. 

Inventor: Stuart H. Yuspa (NCI). 

Publications: 

1. G Rogers, N Martinet, P Steinert, P 

Wynn, D Roop, A Kilkenny, D Morgan, 

SH Yuspa. Cultivation of murine hair 

follicles as organoids in a collagen 

matrix. J Invest Dermatol. 1987 

Oct;89(4):369–379. 

2. W Weinberg, P Brown, WG StetlerStevenson, SH Yuspa, Growth factors 

specifically alter hair follicle cell 

proliferation and collagenolytic activity 

alone or in combination. Differentiation. 

1990 Dec;45(3):168–178. 

Patent Status: U.S. Patent No. 

5,616,471 issued 01 Apr 1997 (HHS 

Reference No. E–213–1987/1–US–01). 

Licensing Status: Available for 

nonexclusive licensing. 

Licensing Contact: Tara Kirby, Ph.D.; 

301/435–4426; tarak@mail.nih.gov. 

Dated: January 9, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–626 Filed 1–17–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Initial Review Group, Subcommittee 

G—Education. 

Date: February 6–7, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Washington Court Hotel, 525 New 

Jersey Avenue, NW., Washington, DC 20001. 

Contact Person: Sonya Roberson, PhD, 

Scientific Review Administrator, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8109, 

Bethesda, MD 20892, 301–594–1182, 

robersos@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: January 9, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–178 Filed 1–17–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Heart, Lung, and Blood 

Advisory Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed blow in 

advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Advisory Council. 

Date: February 14, 2007. 

Open: 8 a.m. to 12 p.m. 

Agenda: Discussion of program policies 

and issues. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 6, Bethesda, MD 20892. 

Closed: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 6, Bethesda, MD 20892. 

Contact Person: Stephen Mockrin, PhD, 

Director, Division of Extramural Research 

Activities, National Heart, Lung, and Blood 

Institute, National Institutes of Health, 6701 

Rockledge Drive, Room 7100, Bethesda, MD 

20892, (301) 435–0260, 

mockrins@nhlbi.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 


pwalker on PROD1PC71 with NOTICES